Shamburg News · 8-K filed Oct 2, 2026, 4:30 PM EDT

Cingulate Extends Trial Period for Chief Medical Officer Matthew Brams' Employment

CING · Cingulate Inc.

  • Leadership change
  • Material agreement
  • Materiality: medium

On September 30, 2026, Cingulate Therapeutics LLC, a wholly owned subsidiary of Cingulate Inc., entered into Amendment No. 2 to the employment agreement with Matthew N. Brams, Executive Vice President and Chief Medical Officer. The amendment extends the trial period for Mr. Brams' full-time employment from September 30, 2026 to December 31, 2026. The amendment is filed as Exhibit 10.1.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 5.02, 9.01, accession 0001493152-26-045527.

Written from the filing by Shamburg Markets. Figures are as reported by the company.